Clinical Trial Update: A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS). [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating tadalafil (LY450190) for lower urinary tract symptoms due to benign prostatic hyperplasia has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• TADALAFIL (TADALAFIL)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Benign Prostatic Hyperplasia | Phase 4 | Status: COMPLETED | Results posted: 2017-03-01